Real World Evidence (RWE), Real World Data (RWD) and the Application of Artificial Intelligence (AI) in Pharma In-house Training

Part of From Inception to Commercialisation: A New Approach to Clinical Data series:

Course overview

Data drives business and all decision making. We need to be aware of its capacity to inform, lead and deliver insights which can be amplified via artificial intelligence (AI).  Data is the fuel; AI is the vehicle. The quest for additional quantitative and qualitative data is boundless and will not relent. All sources should be explored including primary, secondary, pharmacy, community and cursory. This is a dynamic field which will need to be carefully navigated. With increased data, invariably conversations look at the impact of AI. In this course, you will explore the business case for adopting the risk versus reward profile to place your organisation at the heart of the latest thinking.

During the course, you will be able to delve deep into the importance of real world evidence (RWE), real world data (RWD) and explore where new data can add value to your organisation. 

Browse our extensive selection of Life Sciences training courses for industry-leading insights into a range of topics. These include Medical Devices, IVDs, Biotech and Biopharma, Animal Health and Pharmaceutical training courses.

Benefits of attending

• Learn who the key contacts and players are
• Understand which direction the industry is moving in
• Explore timelines
• Know the patient groups and organisations
• Gain an insight into the UK, EU and USA perspective   

Who should attend?

The content will be applicable to the following professionals:

• VPs and managers
• Strategic leaders
• Data scientists and analysts
• Feasibility teams
• Study sets
• Clinical operations
• Regulatory
• Medical affairs
• IT and system integration
• Market access
• Pharmacovigilance and safety
• Diversity and inclusivity teams
• Finance teams and budget holders